Two of them are already available on the market: Conivaptan for the intravenous route [10-16] and Tolvaptan for the oral route [17]. The present data recall that urea is an effective and easy therapeutic choice to correct hyponatremia related to SIADH [18-21] with special attention for patients in the intensive care unit